Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 25,804

Document Document Title
WO/2019/176971A1
Provided is a charge transport material containing a compound represented by the following general formula. R1 and R2 represent a fluorinated alkyl group; Ar1 and Ar2 represent an aromatic ring; A1 and A2 represent an aryl group that is ...  
WO/2019/161495A9
Compounds which inhibits RIPK2, and compositions including such compounds, as well as uses, methods and kits for treating a subject with, or suspected of having, inflammation, an inflammatory disorder and/or a cancer. The invention relat...  
WO/2019/174101A1
The present invention relates to the field of chemical synthesis, and in particular to a method for preparing tenofovir. The compound provided by the present invention has the structure as shown in formula (XII); and the method for prepa...  
WO/2019/172835A1
The invention provides a compound of formula (I) wherein B is a nucleobase; U is O or S; Rx is -OC(=O)Ry, -OC(=O)CH(Ry)NH2, -OCH2OC(=O)Ry; Ry is optionally substituted alkyl or alkenyl or the side chain of a natural or unnatural amino ac...  
WO/2019/170051A1
Disclosed is a DACOs-type NNRTIs amino acid ester derivative, a preparation method thereof, a pharmaceutical composition, and an application thereof. The structure of the DACOs-type NNRTIs amino acid ester derivative of the present inven...  
WO/2019/173507A1
The invention provides compounds of formula (I) or (II) and tautomers and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula (I) or (II) or a tautomer or salt ...  
WO/2019/173602A1
Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can i...  
WO/2019/173506A1
Provided herein are compounds useful for the treatment of various proliferative diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compositions, and may be used in methods ...  
WO/2019/171277A1
The present invention is directed to cycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and / or GPR40 receptors. 5 More particularly, ...  
WO/2019/166532A1
This application relates to quinazoline derivatives of formula (I), pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of ...  
WO/2019/166270A1
The invention relates to an organic electronic device comprising at least one electron transport, electron injection or electron generation layer comprising a compound of Formula (I) wherein all positions which are not linked to a -(A)a-...  
WO/2019/166269A1
The present invention relates to an organic electronic device comprising, between an anode and a cathode, at least one layer selected from an electron injection layer, an electron transport layer or an electron generation layer, the laye...  
WO/2019/167058A1
The present invention relates to an improved process for the preparation of highly pure Propiomazine Maleate of formula-I. More particularly, the invention relates to a cost-effective process, which provides Propiomazine maleate of formu...  
WO/2019/169112A1
Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compound...  
WO/2019/168446A1
The present invention relates to novel compounds of formula (I), which have the properties of a CDK 8/19 inhibitor, and to a pharmaceutical composition containing said compounds, and to the use of said compounds and composition as pharma...  
WO/2019/166206A1
The present invention relates to an organic material and to an electronic device comprising the organic material, particularly to an electroluminescent device, particularly to an organic light emitting diode (OLED), wherein the semicondu...  
WO/2019/166901A1
The invention relates to a process for the synthesis of 6-chloromethyluracil (6-(chloromethyl)pyrimidin-2,4(1H,3H)-dione) from ethyl 4-chloroacetoacetate and S- methylisothiourea hemisulfate via isolation of the novel intermediate 6- (ch...  
WO/2019/165798A1
Disclosed are an unsaturated hydrocarbon pyrimidine thioether compound as represented by formula (I) and a preparation method for and application of the unsaturated hydrocarbon pyrimidine thioether compound. The compound as represented b...  
WO/2019/070709A8
The present invention provides compounds, compositions and methods for treating and/or preventing a flavivirus infection by administering such compounds and compositions.  
WO/2019/167981A1
The present invention relates to: a 4-methyldihydropyrimidinone compound having an ROR-γ antagonistic activity or a pharmacologically acceptable salt of the compound; a medicinal composition containing the compound or salt; and a medici...  
WO/2019/167982A1
The present invention pertains to: a saturated ring-condensed dihydropyrimidinone or dihydrotriazinone compound having RORγ antagonist activity or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing same;...  
WO/2019/164846A1
The present invention relates to N-(phenyl)-2-(phenyl)pyrimidine-4- carboxamide derivatives and related compounds of formula I as HPK1 (Hematopoietic progenitor kinase 1) inhibitors for treating cancer, such as e.g. breast cancer, colore...  
WO/2019/164799A1
Methods of treating non-alcoholic steatohepatisis (NASH), non-alcoholic fatty liver disease (NAFLD), fatty acid liver disease (FALD), alcoholic liver disease, and/or liver fibrosis in a mammal by administering a lyn kinase activator are ...  
WO/2019/161495A1
Compounds which inhibits RIPK2, and compositions including such compounds, as well as uses, methods and kits for treating a subject with, or suspected of having, inflammation, an inflammatory disorder and/or a cancer. The invention relat...  
WO/2019/165290A1
The invention provides a compound as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and methods for using such compounds and compositions. Formula (I).  
WO/2019/159596A1
Provided is a method for preparing a coupled body represented by general formula (3), the coupled body being obtained by reacting a compound represented by general formula (1) and a compound represented by general formula (2) in the pres...  
WO/2018/118791A9
Novel quinazolinones useful as inhibitors of tau oligomer formation, useful for the treatment of neurodegenerative diseases and related conditions are disclosed. The invention also relates to the pharmaceutically acceptable salts of said...  
WO/2019/161162A1
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).  
WO/2019/155399A1
Compounds of the general formula: processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.  
WO/2019/154091A1
Provided are a substituted diaminopyrimidine compound as represented by formula (I), or a pharmaceutically acceptable salt, crystal form, prodrug, metabolite, hydrate, solvate, stereoisomer or isotopic derivative thereof, and a pharmaceu...  
WO/2019/156405A1
The present specification provides a compound and an organic light emitting device comprising the same.  
WO/2019/076329A9
The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N-H, O, S, or absent; (II) is a single bond or a double bond; each of X,...  
WO/2019/149128A1
The present invention provides a 5-chloro-2,4-pyrimidine derivative used as an anaplastic lymphoma kinase (ALK) inhibitor. The derivative is a compound represented by formula I or a pharmaceutically acceptable salt, prodrug, hydrate, sol...  
WO/2019/126136A3
The present disclosure provides pyrimidine compounds useful as tyrosine kinase inhibitors, and particularly epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors. The disclosed EGFR inhibi...  
WO/2019/152373A1
The present invention provides methods of synthesizing (6S,15S)-3,8,13,18-tetraazaicosane-6,15-diol and salts thereof.  
WO/2019/152187A1
The present disclosure provides a redox initiator system for initiating polymerization comprising an oxidizing agent, a photolabile reducing agent derived from a barbiturate, and a transition metal complex that participates in a redox cy...  
WO/2019/149164A1
Disclosed are compounds inhibiting ErbBs (e. g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the com...  
WO/2019/148036A1
Disclosed herein are compounds of Formula (I'). Compounds of Formula (I') inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned...  
WO/2019/090158A9
The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject ar...  
WO/2019/143860A1
Provided herein are 5-fluorouracil derived acetal and hemiaminal ether compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.  
WO/2019/143874A1
The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is...  
WO/2019/143678A1
The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various d...  
WO/2019/141009A1
Disclosed are a compound and a pharmaceutically acceptable salt thereof, which can be used, by means of a chemical small molecule which targets both UHRF1 and HDAC1, or a pharmaceutically acceptable salt thereof, as corresponding inhibit...  
WO/2019/142192A1
Novel compounds capable of inhibiting methionine metabolic pathway are provided. These compounds are used in inhibiting cystathionin γ-synthase (CGS) in general, and in plants, fungi and bacteria, in particular. These compounds of the i...  
WO/2019/139185A1
The present disclosure relates to a method for preparing tolimidone on large scale with maintaining high purity and uniform particle size distribution, and more specifically, a method suitable for preparing tolimidone on industrially lar...  
WO/2019/140095A1
The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as stimulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparatio...  
WO/2019/139919A1
Disclosed herein are acetal and cyclic acetal compounds, compositions, their preparation, and their uses. Some embodiments relate to their use as liver-targeting compounds.  
WO/2019/135405A1
A method for detecting an analog that is derived from trifluridine, the method including a step for subjecting a sample that includes trifluridine or a salt thereof to high-speed liquid chromatography that uses a mobile phase that compri...  
WO/2019/134082A1
Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds function as inhibitors of MTH1. Preferred compounds are useful in the treatment of cancer or other diseases, where inhibition of M...  
WO/2019/129213A1
Disclosed are an amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines. The compound or the ph...  

Matches 1 - 50 out of 25,804